The tablet formulation of the anticancer drug ‘Lynparza’ can now be prescribed at the Big-5 tertiary hospitals.

Industry sources reported that AstraZeneca’s poly ADP ribose polymerase (PARP) inhibitor Lynparza (olaparib) passed the review of drug committees (DC) in the five major hospitals, the ‘Big-5s,’ which include the Samsung Medical Center, Seoul National University Hospital, Seoul St. Mary’s Hospital, Asan Medical Center, and Severance Hospital. With Severance Hospital’s DC giving the last nod, Lynparza has now landed in all five hospitals as well as 25 other medical institutions nationwide.

As the company received approval from HIRA's Drug Review Evaluation